| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9149(96)00152-X |
| P8608 | Fatcat ID | release_3bfnuzu4xfbllp2ns6j2tx67sa |
| P698 | PubMed publication ID | 8651085 |
| P2093 | author name string | Kornowski R | |
| Roth A | |||
| Glick A | |||
| Keren G | |||
| Laniado S | |||
| Koifman B | |||
| Michowich Y | |||
| P2860 | cites work | Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris | Q70625383 |
| Persistent activation of coagulation mechanism in unstable angina and myocardial infarction | Q72047945 | ||
| Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction | Q72442083 | ||
| Are we mortgaging the medical profession? | Q95814757 | ||
| Reactivation of unstable angina after the discontinuation of heparin | Q28186187 | ||
| An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 | ||
| The pathogenesis of coronary artery disease and the acute coronary syndromes (2). | Q36730913 | ||
| Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommitte | Q37942611 | ||
| Platelets and thrombolytic therapy | Q38014728 | ||
| Left ventricular function at 3 months after successful thrombolysis. Impact of reocclusion without reinfarction on ejection fraction, regional function, and remodeling | Q41016970 | ||
| Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia | Q41675350 | ||
| Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes | Q42281372 | ||
| Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial | Q47384123 | ||
| Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis | Q47409206 | ||
| Effect of coronary reocclusion after initial reperfusion on ventricular function and infarct size | Q47425721 | ||
| Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II | Q68084255 | ||
| Reocclusion three months after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex | Q68517506 | ||
| Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group | Q68902956 | ||
| Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality | Q69292102 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heparin | Q190016 |
| Streptokinase | Q416485 | ||
| P304 | page(s) | 1145-1148 | |
| P577 | publication date | 1996-06-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction | |
| P478 | volume | 77 |
| Q34531478 | Acute ischemic syndromes. Adjunctive therapy |
| Q24806932 | Arterial indications for the low molecular weight heparins |
| Q33989688 | Assessment of low-molecular-weight heparin trials in cardiology |
| Q45212097 | Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarct |
| Q37414802 | Efficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction |
| Q37445888 | Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction |
| Q77120999 | Enoxaparin. A review of its clinical potential in the management of coronary artery disease |
| Q34698784 | Enoxaparin: an update of its clinical use in the management of acute coronary syndromes. |
| Q36035257 | Evolving role of low-molecular-weight heparins in ST-elevation myocardial infarction |
| Q33881653 | Formulary management of low molecular weight heparins |
| Q47228689 | Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction |
| Q43942828 | Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction |
| Q40829792 | Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease |
| Q34051300 | Ischemic complications after percutaneous transluminal coronary angioplasty |
| Q47269645 | Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). |
| Q33499141 | Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations |
| Q34158943 | Low molecular weight heparins for arterial thrombosis |
| Q34140745 | Low-molecular weight heparins in coronary artery disease |
| Q36110453 | Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction |
| Q41707230 | Low-molecular-weight heparins for acute coronary syndromes |
| Q47234707 | Low-molecular-weight heparins in acute myocardial infarction: rationale and results of a pilot study |
| Q36545687 | Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature |
| Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
| Q53358418 | Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. |
| Q47301819 | Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study |
| Q33904621 | Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction |
| Q34071460 | The role of low-molecular-weight heparins in arterial diseases: optimizing antithrombotic therapy |
| Q33357627 | The use of Low Molecular Weight Heparin to Predict Clinical Outcome in Patients with Unstable Angina That Had Undergone Percutaneous Coronary Intervention |
| Q33955195 | Thrombolytic therapy in acute myocardial infarction |
| Q35081866 | Thrombolytic therapy: clinical applications |
| Q37031371 | Utilizing enoxaparin in the management of STEMI. |
Search more.